 |
Day
Two |
| DAY
ONE |
Tuesday 29 January
2002
|
| 08.45
|
Chairmans
Opening Welcome
Falk
Strascheg, Founder and Managing Partner, Extorel
|
| 09.00
|
State of
the European Private Equity Market
Frank
Brechlin, Private Equity Advisor,
Bank Vontobel AG |
| 09.20 |
Key Investment
Themes in 2002
Stephen
Murphy , Managing Director
Schroder Salomon Smith Barney |
| 09.40
|
The Biotech
Sector Recent Trends in Financing
Franc Gregori,
Head of Pharmaceutical, Healthcare and BioTech Research,
BNP Paribas
|
| 10.00 |
The Impact of Genomics on Drug Discovery & Development
Dr. Ismail Kola, Vice President, Discovery Research and Global
Head: Genomics Sciences & Pharmacogenomics, Pharmacia
Corporation
|
| 10.20 |
The IPO
Market in Europe: Quo Vadis?
Frances
Bornstein, Deputy Head SWX New Market, SWX
Swiss Exchange |
| 10.40 |
Break
|
|
|
Chair
Dr. Christian
Zschocke, Managing Partner, Morgan
Lewis & Bockius |
| 11.00
|
Emerging
Business Markets
David
McKenzie,, Business Development Executive,
IBM NetGeneration |
| 11.20
|
M&A
Mission Critical in Early Stage VC
Friedrich
Bornikoel, Managing Partner,
TVM Techno
Venture Management |
| 11.40 |
Analysing
Europe: The Next Major Developments
Toon
den Heijer, Executive Director, Gilde
IT Fund |
| 12.00 |
Business
Process Integration - One Next Big Thing
Dr. Hans-Dieter
Koch, CEO, b-business
partners |
| 12.20 |
Maturation
of Entrepreneurship in Europe: Building Block for the Establishment
of a Sophisticated VC Environment in Europe
Mr
Eric Achtmann, Partner, PolyTechnos
Venture-Partners |
| 12.40 |
Lunch
|
| |
|
|
14.00
Dr
CEO
|
|
14.20
Strat
Man
Dr
and
Nov
|
14.40
15.25 |
|
|
Business Models for
CAT and Biotech
Dr.
David Chiswell, CEO,
Cambridge Antibody
Trust
|
Biopartnering and Technology Transfer
as Strategic Success Factors in the Management of Innovation
Dr.
Romeo Paioni, Head of Scientific and
External Affairs,
Novartis
Pharma AG
|
BIOTECH
PANEL
Prof.
Dr. Horst Domdey,
CEO, Bio-M
AG
Steve
Burrill,
CEO, Burrill
& Co
Dr.
Jörg Neermann,
Managing Partner,
DVC
Deutsche Venture Capital
|
|
|
|
| 15.30 |
STREAMED COMPANY PRESENTATION WORKSHOPS
Featuring up to 60 Start-Up Pre-IPO Companies
|
| 19.00 |
COCKTAIL
RECEPTION |
| DAY
TWO |
Wednesday
30 January 2002 |
| 08.30 |
Chair
Harald Ehren, Inside Business,
Financial Times Deutschland
INTRODUCTORY ADDRESS*
Hans
Spitzner,
Vice Minister and State Secretary,
Bavarian Ministry for Economic Affairs, Transport
& Technology |
| 08.40 |
The Great Silicon Valley Swindle
Paul
Abrahams, Silicon Valley Bureau Chief, Financial
Times
|
| 09.00 |
Venture
Capital Landscape in Germany
Dr. Hans-Christian
Perle, Investment Director
Ad_Astra
Venture Consult GmbH |
| 09.20 |
The Cambridge
Cluster A Bottom-Up Initiative
Tim Minshall,
Member of the Board
St Johns
Innovation Centre Ltd |
| 09.40 |
Trends
and Prospects in New Technologies
Dr. Ralf-Dieter
Schnell, General Managing Director
Infineon
Ventures |
| 10.00 |
Value Added
Services Provided by VCs
Michael
Mathiesen, President & CEO,
2M Invest |
| 10.20 |
Break |
|
10.40
Chair
Ven
Bar
Alta
Tim
Int
Ste
E.ON
|
|
11.25
|
|
New Technologies
Chair Holger
Heims, Managing Partner,
DVC Deutsche Venture Capital
Barun
Dutta, CTO,
Alta Berkeley Venture Partners
Tim
Keating, Director,
Intel Capital Europe
Steffen
Hasselwander, CEO,
E.ON Venture Partners
|
Israel as a Technology Innovator
Chair Zeev
Holtzman, Board Member,
IVA Israel Venture
Association & Founder, Chairman
& CEO, Giza
Venture Capital
Dr.
Eli Carmon, Manager,
KPMG Somekh Chaikin
Chemi
Peres, Managing Director & Founder,
Pitango Venture Capital
Jon
Medved, General Partner & Founder,
Israel Seed Partners
|
|
|
|
|
12.10 |
Investor
Panel
Chair Alf
Grunwald, Managing Director,
Warburg Pincus
Maximilian
Brönner, Partner, LGT
Capital Partners
Dr.
Holger Frommann, Managing Director,
BVK
Dr.
Ulrich Geilinger, Board Member,
HBM Partners AG |
| 13.00 |
Lunch
|
| 14.15 |
|
|
| NEW
TECHNOLOGIES |
SECURITY
TECHNOLOGIES /
NANOTECHNOLOGY |
|
|
| 17.00 |
Close of Conference |
| *tbc |
back
to top |
|